- Home
- PHGE vs BCLI Comparison
PHGE vs BCLI Comparison
Compare PHGE & BCLI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PHGE
- BCLI
- Stock Information
- Founded
- PHGE 2015
- BCLI 2000
- Country
- PHGE Israel
- BCLI United States
- Employees
- PHGE N/A
- BCLI N/A
- Industry
- PHGE Biotechnology: Pharmaceutical Preparations
- BCLI Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- PHGE Health Care
- BCLI Health Care
- Exchange
- PHGE Nasdaq
- BCLI Nasdaq
- Market Cap
- PHGE 11.0M
- BCLI 9.8M
- IPO Year
- PHGE N/A
- BCLI N/A
- Fundamental
- Price
- PHGE $0.44
- BCLI $1.17
- Analyst Decision
- PHGE Strong Buy
- BCLI Strong Buy
- Analyst Count
- PHGE 1
- BCLI 1
- Target Price
- PHGE $15.00
- BCLI $30.00
- AVG Volume (30 Days)
- PHGE 284.6K
- BCLI 415.6K
- Earning Date
- PHGE 08-13-2025
- BCLI 08-13-2025
- Dividend Yield
- PHGE N/A
- BCLI N/A
- EPS Growth
- PHGE N/A
- BCLI N/A
- EPS
- PHGE N/A
- BCLI N/A
- Revenue
- PHGE N/A
- BCLI N/A
- Revenue This Year
- PHGE N/A
- BCLI N/A
- Revenue Next Year
- PHGE N/A
- BCLI N/A
- P/E Ratio
- PHGE N/A
- BCLI N/A
- Revenue Growth
- PHGE N/A
- BCLI N/A
- 52 Week Low
- PHGE $0.34
- BCLI $0.72
- 52 Week High
- PHGE $3.86
- BCLI $6.45
- Technical
- Relative Strength Index (RSI)
- PHGE 43.34
- BCLI 50.82
- Support Level
- PHGE $0.43
- BCLI $1.02
- Resistance Level
- PHGE $0.48
- BCLI $1.32
- Average True Range (ATR)
- PHGE 0.05
- BCLI 0.09
- MACD
- PHGE 0.00
- BCLI -0.01
- Stochastic Oscillator
- PHGE 58.82
- BCLI 50.00
About PHGE BiomX Inc. COmmon Stock
BiomX Inc is engaged in developing both natural and engineered phage cocktails and personalized treatments designed to target and destroy harmful bacteria in chronic diseases, including cystic fibrosis and diabetic foot osteomyelitis. It discovers and validates proprietary bacterial targets and customizes phage compositions against these targets, and applies its BOLT (BacteriOphage Lead to Treatment) platform to customize phage compositions against these targets. BX004 is its therapeutic phage product candidate under development for chronic pulmonary infections caused by Pseudomonas aeruginosa, or P. aeruginosa, a main contributor to morbidity and mortality in patients with CF. Its BX211 - Treatment of Diabetic Foot Osteomyelitis (DFO).
About BCLI Brainstorm Cell Therapeutics Inc.
Brainstorm Cell Therapeutics Inc is a biotechnology company. The company is developing novel adult stem cell therapies for debilitating neurodegenerative disorders such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig's disease), Progressive Multiple Sclerosis (PMS), and Parkinson's disease (PD). Brainstorm's NurOwn, its proprietary process for the propagation of Mesenchymal Stem Cells (MSC) and differentiation into neurotrophic factor-(NTF) secreting cells (MSC-NTF), and their transplantation at, or near, the site of damage, offers the hope of more effectively treating neurodegenerative diseases.